Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Early trial results show that immunotherapy using chimeric antigen receptor (CAR) T-cell therapy may be effective in patients with multiple myeloma. 
No comment yet.
Sign up to comment
|
Scoop.it!
BigField GEG Tech's insight:
The scientists used cellular reprogramming and genome engineering to functionally dissect the loss of chromosome 7q, a somatic cytogenetic abnormality present in myelodysplastic syndromes. They used a phenotype-rescue screen to identify candidate haploinsufficient genes that might mediate the del(7q)- hematopoietic defect. Their approach highlights the utility of human iPSCs both for functional mapping of disease-associated large-scale chromosomal deletions and for discovery of haploinsufficient genes.
|
Last year results from two early clinical trials indicated that immunotherapy using chimeric antigen receptor (CAR) T-cell therapy may be effective in patients with multiple myeloma